An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers
Purpose The swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to identify optimal platforms. To probe the significance of antibody format on image quality for PD-L1 imaging, we developed and studied th...
Saved in:
| Published in | Molecular imaging and biology Vol. 22; no. 6; pp. 1553 - 1561 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cham
Springer International Publishing
01.12.2020
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1536-1632 1860-2002 1860-2002 |
| DOI | 10.1007/s11307-020-01527-3 |
Cover
| Abstract | Purpose
The swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to identify optimal platforms. To probe the significance of antibody format on image quality for PD-L1 imaging, we developed and studied the biodistribution of a library of antibodies based on the anti-PD-L1 IgG1 clone C4.
Procedure
A C4 minibody and scFv were cloned, expressed, and characterized. The antibodies were functionalized with desferrioxamine and radiolabeled with Zr-89 to enable a rigorous comparison with prior data collected using
89
Zr-labeled C4 IgG1. The biodistribution of the radiotracers was evaluated in C57Bl6/J or nu/nu mice bearing B16F10 or H1975 tumors, respectively, which are models that represent high and low tumor autonomous PD-L1 expression.
Results
The tumor uptake of the
89
Zr-C4 minibody was higher than
89
Zr-C4 scFv and equivalent to previous data collected using
89
Zr-C4 IgG1. However, the peak tumors to normal tissue ratios were generally higher for
89
Zr-C4 scFv compared with
89
Zr-C4 minibody and
89
Zr-IgG1. Moreover, an exploratory study showed that the rapid clearance of
89
Zr-C4 scFv enabled detection of endogenous PD-L1 on a genetically engineered and orthotopic model of hepatocellular carcinoma.
Conclusion
In summary, these data support the use of low molecular weight constructs for PD-L1 imaging, especially for tumor types that manifest in abdominal organs that are obstructed by the clearance of high molecular weight radioligands. |
|---|---|
| AbstractList | The swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to identify optimal platforms. To probe the significance of antibody format on image quality for PD-L1 imaging, we developed and studied the biodistribution of a library of antibodies based on the anti-PD-L1 IgG1 clone C4.PURPOSEThe swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to identify optimal platforms. To probe the significance of antibody format on image quality for PD-L1 imaging, we developed and studied the biodistribution of a library of antibodies based on the anti-PD-L1 IgG1 clone C4.A C4 minibody and scFv were cloned, expressed, and characterized. The antibodies were functionalized with desferrioxamine and radiolabeled with Zr-89 to enable a rigorous comparison with prior data collected using 89Zr-labeled C4 IgG1. The biodistribution of the radiotracers was evaluated in C57Bl6/J or nu/nu mice bearing B16F10 or H1975 tumors, respectively, which are models that represent high and low tumor autonomous PD-L1 expression.PROCEDUREA C4 minibody and scFv were cloned, expressed, and characterized. The antibodies were functionalized with desferrioxamine and radiolabeled with Zr-89 to enable a rigorous comparison with prior data collected using 89Zr-labeled C4 IgG1. The biodistribution of the radiotracers was evaluated in C57Bl6/J or nu/nu mice bearing B16F10 or H1975 tumors, respectively, which are models that represent high and low tumor autonomous PD-L1 expression.The tumor uptake of the 89Zr-C4 minibody was higher than 89Zr-C4 scFv and equivalent to previous data collected using 89Zr-C4 IgG1. However, the peak tumors to normal tissue ratios were generally higher for 89Zr-C4 scFv compared with 89Zr-C4 minibody and 89Zr-IgG1. Moreover, an exploratory study showed that the rapid clearance of 89Zr-C4 scFv enabled detection of endogenous PD-L1 on a genetically engineered and orthotopic model of hepatocellular carcinoma.RESULTSThe tumor uptake of the 89Zr-C4 minibody was higher than 89Zr-C4 scFv and equivalent to previous data collected using 89Zr-C4 IgG1. However, the peak tumors to normal tissue ratios were generally higher for 89Zr-C4 scFv compared with 89Zr-C4 minibody and 89Zr-IgG1. Moreover, an exploratory study showed that the rapid clearance of 89Zr-C4 scFv enabled detection of endogenous PD-L1 on a genetically engineered and orthotopic model of hepatocellular carcinoma.In summary, these data support the use of low molecular weight constructs for PD-L1 imaging, especially for tumor types that manifest in abdominal organs that are obstructed by the clearance of high molecular weight radioligands.CONCLUSIONIn summary, these data support the use of low molecular weight constructs for PD-L1 imaging, especially for tumor types that manifest in abdominal organs that are obstructed by the clearance of high molecular weight radioligands. Purpose The swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to identify optimal platforms. To probe the significance of antibody format on image quality for PD-L1 imaging, we developed and studied the biodistribution of a library of antibodies based on the anti-PD-L1 IgG1 clone C4. Procedure A C4 minibody and scFv were cloned, expressed, and characterized. The antibodies were functionalized with desferrioxamine and radiolabeled with Zr-89 to enable a rigorous comparison with prior data collected using 89 Zr-labeled C4 IgG1. The biodistribution of the radiotracers was evaluated in C57Bl6/J or nu/nu mice bearing B16F10 or H1975 tumors, respectively, which are models that represent high and low tumor autonomous PD-L1 expression. Results The tumor uptake of the 89 Zr-C4 minibody was higher than 89 Zr-C4 scFv and equivalent to previous data collected using 89 Zr-C4 IgG1. However, the peak tumors to normal tissue ratios were generally higher for 89 Zr-C4 scFv compared with 89 Zr-C4 minibody and 89 Zr-IgG1. Moreover, an exploratory study showed that the rapid clearance of 89 Zr-C4 scFv enabled detection of endogenous PD-L1 on a genetically engineered and orthotopic model of hepatocellular carcinoma. Conclusion In summary, these data support the use of low molecular weight constructs for PD-L1 imaging, especially for tumor types that manifest in abdominal organs that are obstructed by the clearance of high molecular weight radioligands. PurposeThe swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to identify optimal platforms. To probe the significance of antibody format on image quality for PD-L1 imaging, we developed and studied the biodistribution of a library of antibodies based on the anti-PD-L1 IgG1 clone C4.ProcedureA C4 minibody and scFv were cloned, expressed, and characterized. The antibodies were functionalized with desferrioxamine and radiolabeled with Zr-89 to enable a rigorous comparison with prior data collected using 89Zr-labeled C4 IgG1. The biodistribution of the radiotracers was evaluated in C57Bl6/J or nu/nu mice bearing B16F10 or H1975 tumors, respectively, which are models that represent high and low tumor autonomous PD-L1 expression.ResultsThe tumor uptake of the 89Zr-C4 minibody was higher than 89Zr-C4 scFv and equivalent to previous data collected using 89Zr-C4 IgG1. However, the peak tumors to normal tissue ratios were generally higher for 89Zr-C4 scFv compared with 89Zr-C4 minibody and 89Zr-IgG1. Moreover, an exploratory study showed that the rapid clearance of 89Zr-C4 scFv enabled detection of endogenous PD-L1 on a genetically engineered and orthotopic model of hepatocellular carcinoma.ConclusionIn summary, these data support the use of low molecular weight constructs for PD-L1 imaging, especially for tumor types that manifest in abdominal organs that are obstructed by the clearance of high molecular weight radioligands. |
| Author | Ruggero, Davide Seo, Youngho Fong, Lawrence Wei, Junnian Oh, David Y. Craik, Charles S. Flavell, Robert R. Wang, Yung-hua Wang, Cheng-I Lee, Chia Yin Truillet, Charles Xu, Yichen VanBrocklin, Henry F. Evans, Michael J. |
| AuthorAffiliation | 1 Department of Radiology and Biomedical Imaging, University of California San Francisco 505 Parnassus Ave, San Francisco CA 94143 5 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 505 Parnassus Ave, San Francisco CA 94143 3 Imagerie Moleculaire In Vivo, INSERM, CEA, Univ. Paris Sud, CNRS, Universite Paris Saclay, CEA-Service Hospitalier Frederic Joliot, Orsay France, 94100 7 Department of Pharmaceutical Chemistry, University of California San Francisco, 505 Parnassus Ave, San Francisco CA 94143 6 Department of Urology, University of California San Francisco, 505 Parnassus Ave, San Francisco CA 94143 2 Singapore Immunology Network, Agency for Science, Technology and Research (ASTAR), 8A Biomedical Grove Immunos #03-06, Biopolis Singapore 138648 4 Department of Medicine, University of California San Francisco, 513 Parnassus Ave, San Francisco CA 94143 |
| AuthorAffiliation_xml | – name: 7 Department of Pharmaceutical Chemistry, University of California San Francisco, 505 Parnassus Ave, San Francisco CA 94143 – name: 3 Imagerie Moleculaire In Vivo, INSERM, CEA, Univ. Paris Sud, CNRS, Universite Paris Saclay, CEA-Service Hospitalier Frederic Joliot, Orsay France, 94100 – name: 4 Department of Medicine, University of California San Francisco, 513 Parnassus Ave, San Francisco CA 94143 – name: 2 Singapore Immunology Network, Agency for Science, Technology and Research (ASTAR), 8A Biomedical Grove Immunos #03-06, Biopolis Singapore 138648 – name: 6 Department of Urology, University of California San Francisco, 505 Parnassus Ave, San Francisco CA 94143 – name: 5 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 505 Parnassus Ave, San Francisco CA 94143 – name: 1 Department of Radiology and Biomedical Imaging, University of California San Francisco 505 Parnassus Ave, San Francisco CA 94143 |
| Author_xml | – sequence: 1 givenname: Junnian surname: Wei fullname: Wei, Junnian organization: Department of Radiology and Biomedical Imaging, University of California San Francisco – sequence: 2 givenname: Yung-hua surname: Wang fullname: Wang, Yung-hua organization: Department of Radiology and Biomedical Imaging, University of California San Francisco – sequence: 3 givenname: Chia Yin surname: Lee fullname: Lee, Chia Yin organization: Singapore Immunology Network, Agency for Science, Technology and Research (ASTAR) – sequence: 4 givenname: Charles surname: Truillet fullname: Truillet, Charles organization: Imagerie Moleculaire In Vivo, INSERM, CEA, Univ. Paris Sud, CNRS, Universite Paris Saclay, CEA-Service Hospitalier Frederic Joliot – sequence: 5 givenname: David Y. surname: Oh fullname: Oh, David Y. organization: Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco – sequence: 6 givenname: Yichen surname: Xu fullname: Xu, Yichen organization: Department of Urology, University of California San Francisco – sequence: 7 givenname: Davide surname: Ruggero fullname: Ruggero, Davide organization: Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Department of Urology, University of California San Francisco – sequence: 8 givenname: Robert R. surname: Flavell fullname: Flavell, Robert R. organization: Department of Radiology and Biomedical Imaging, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco – sequence: 9 givenname: Henry F. surname: VanBrocklin fullname: VanBrocklin, Henry F. organization: Department of Radiology and Biomedical Imaging, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco – sequence: 10 givenname: Youngho surname: Seo fullname: Seo, Youngho organization: Department of Radiology and Biomedical Imaging, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco – sequence: 11 givenname: Charles S. surname: Craik fullname: Craik, Charles S. organization: Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Department of Pharmaceutical Chemistry, University of California San Francisco – sequence: 12 givenname: Lawrence surname: Fong fullname: Fong, Lawrence organization: Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco – sequence: 13 givenname: Cheng-I surname: Wang fullname: Wang, Cheng-I organization: Singapore Immunology Network, Agency for Science, Technology and Research (ASTAR) – sequence: 14 givenname: Michael J. orcidid: 0000-0003-4947-1316 surname: Evans fullname: Evans, Michael J. email: michael.evans@ucsf.edu organization: Department of Radiology and Biomedical Imaging, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Department of Pharmaceutical Chemistry, University of California San Francisco |
| BookMark | eNqNUU1vEzEUXKEi-gF_gJMlLlwW_PzWa-eCFPUDKqWiKkUcLcfr3bhy1sHeJeTf4yWRKnqoOPnpeWY0b-a0OOpDb4viLdAPQKn4mACQipIyWlLgTJT4ojgBWdOSUcqO8syxLqFGdlycpvRAKQhg-Ko4RiYBAdhJ8Xvek3mv_S65REJLrlMwPuRF3g5uGZoduQpxrYdEvo1dZ1MeNLkL3pI2RHJjdRqj6ztye1EugGzdsCKLsCU3GWFGryP5YV23Gsjt5T25040LQ9TGxvS6eNlqn-ybw3tWfL-6vD__Ui6-fr4-ny9KU3EYSmioFlWll4i1NaLChiOjy-x-JmeWtUYgrRrKGEfZoBVWCs3RzgA5WGsAzwrc6479Ru-22nu1iW6t404BVVOOap-jyjmqvzkqzKxPe9ZmXK5tY2yfbT8yg3bq35_erVQXfilR17NaVlng_UEghp9jjk2tXTLWe93bMCbFKuQ8VwAyQ989gT6EMeYKJpRAIflMTo7YHmViSCna9v_OkE9Ixg16cGEy7fzz1ENuaTP1a-Ojq2dYfwAVMscn |
| CitedBy_id | crossref_primary_10_3390_cells10113165 crossref_primary_10_3390_cells10113166 crossref_primary_10_2967_jnumed_124_268586 crossref_primary_10_1016_j_adro_2022_100936 crossref_primary_10_1021_acs_molpharmaceut_2c00497 crossref_primary_10_3390_biomedicines10020236 crossref_primary_10_1002_smtd_202400358 crossref_primary_10_1016_j_jpha_2022_09_001 crossref_primary_10_3390_jpm11121312 crossref_primary_10_3390_ijms222212314 crossref_primary_10_2967_jnumed_121_262967 crossref_primary_10_3390_ijms222212297 crossref_primary_10_3390_ijms222212330 |
| Cites_doi | 10.1021/acs.molpharmaceut.9b00010 10.1038/s41591-018-0321-2 10.1021/acs.bioconjchem.8b00632 10.1200/JCO.2012.42.4887 10.1158/1535-7163.MCT-14-0983 10.7150/thno.37924 10.2967/jnumed.116.177659 10.1038/s41568-019-0116-x 10.1038/s41467-018-07131-y 10.2967/jnumed.116.177493 10.1039/C9CC00445A 10.1038/s41591-018-0255-8 10.2967/jnumed.117.199596 10.1021/acs.molpharmaceut.8b00399 10.1021/acs.bioconjchem.7b00631 10.1016/j.ccell.2014.12.004 10.1186/s40425-019-0768-9 10.2967/jnumed.119.240895 |
| ContentType | Journal Article |
| Copyright | World Molecular Imaging Society 2020 World Molecular Imaging Society 2020. |
| Copyright_xml | – notice: World Molecular Imaging Society 2020 – notice: World Molecular Imaging Society 2020. |
| DBID | AAYXX CITATION 7QO 8FD FR3 K9. NAPCQ P64 7X8 5PM ADTOC UNPAY |
| DOI | 10.1007/s11307-020-01527-3 |
| DatabaseName | CrossRef Biotechnology Research Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) |
| Database_xml | – sequence: 1 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1860-2002 |
| EndPage | 1561 |
| ExternalDocumentID | oai:pubmedcentral.nih.gov:7669684 PMC7669684 10_1007_s11307_020_01527_3 |
| GrantInformation_xml | – fundername: National Institute of Biomedical Imaging and Bioengineering grantid: R01EB025207 funderid: http://dx.doi.org/10.13039/100000070 – fundername: American Cancer Society grantid: 130635-RSG-17-005-01-CCE funderid: http://dx.doi.org/10.13039/100000048 – fundername: Prostate Cancer Foundation grantid: N/A funderid: http://dx.doi.org/10.13039/100000892 – fundername: National Cancer Institute grantid: 130635-RSG-17-005-01-CCE; U01CA233100; U01CA244452; P41CA196276; R35CA242986; P30CA082103 funderid: http://dx.doi.org/10.13039/100000054 |
| GroupedDBID | --- --K -5E -5G -BR -EM -Y2 -~C .86 .VR 04C 06C 06D 0R~ 0VY 123 1B1 1N0 203 29M 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5VS 67Z 6NX 7RV 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAEDT AAHNG AAIAL AAJBT AAJKR AALRI AANXM AANZL AAQFI AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAXUO AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJCF ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABWVN ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIUM ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACRPL ACSNA ACZOJ ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADMUD ADNMO ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRDE AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBNVY BDATZ BENPR BGLVJ BGNMA BHPHI BKEYQ BMSDO BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIHBH EIOEI EJD EMOBN EN4 ESBYG EX3 F5P FDB FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HCIFZ HF~ HG5 HG6 HLICF HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH L6V LK8 LLZTM M1P M41 M4Y M7P M7S MA- N2Q NAPCQ NB0 NPVJJ NQ- NQJWS NU0 O9- O93 O9I O9J OAM P9S PF0 PQQKQ PROAC PSQYO PT4 PTHSS Q2X QOR QOS R89 R9I RIG RNS ROL RPX RPZ RRX RSV S16 S1Z S27 S37 S3B SAP SDH SEW SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC TUS U2A U9L UG4 UHS UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW YLTOR Z45 Z7U Z7X Z82 Z83 Z87 ZMTXR ZOVNA ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ACVFH ADCNI ADHKG AEUPX AEZWR AFDZB AFHIU AFOHR AFPUW AGQPQ AHPBZ AHWEU AIGII AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PQGLB PUEGO 7QO 8FD FR3 K9. P64 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c451t-1d0a744ab336ec743d5320b131989e2fc7304d022538d3e7e87a53e91351eec13 |
| IEDL.DBID | U2A |
| ISSN | 1536-1632 1860-2002 |
| IngestDate | Sun Oct 26 04:05:23 EDT 2025 Thu Aug 21 14:10:28 EDT 2025 Fri Sep 05 10:20:33 EDT 2025 Tue Oct 07 06:37:37 EDT 2025 Thu Apr 24 23:04:44 EDT 2025 Wed Oct 01 02:09:30 EDT 2025 Fri Feb 21 02:36:52 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Immune checkpoint inhibitor Precision medicine Immunotherapy Predictive biomarker Cancer |
| Language | English |
| License | Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. http://www.springer.com/gb/open-access/authors-rights/aam-terms-v1 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c451t-1d0a744ab336ec743d5320b131989e2fc7304d022538d3e7e87a53e91351eec13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally. |
| ORCID | 0000-0003-4947-1316 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.ncbi.nlm.nih.gov/pmc/articles/7669684 |
| PMID | 32813112 |
| PQID | 2473785983 |
| PQPubID | 55372 |
| PageCount | 9 |
| ParticipantIDs | unpaywall_primary_10_1007_s11307_020_01527_3 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7669684 proquest_miscellaneous_2435531118 proquest_journals_2473785983 crossref_primary_10_1007_s11307_020_01527_3 crossref_citationtrail_10_1007_s11307_020_01527_3 springer_journals_10_1007_s11307_020_01527_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-12-01 |
| PublicationDateYYYYMMDD | 2020-12-01 |
| PublicationDate_xml | – month: 12 year: 2020 text: 2020-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: New York |
| PublicationTitle | Molecular imaging and biology |
| PublicationTitleAbbrev | Mol Imaging Biol |
| PublicationYear | 2020 |
| Publisher | Springer International Publishing Springer Nature B.V |
| Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
| References | Mayer, Natarajan, Gordon, Maute, McCracken, Ring, Weissman, Gambhir (CR19) 2017; 58 Bensch, van der Veen, Lub-de Hooge, Jorritsma-Smit, Boellaard, Kok, Oosting, Schröder, Hiltermann, van der Wekken, Groen, Kwee, Elias, Gietema, Bohorquez, de Crespigny, Williams, Mancao, Brouwers, Fine, de Vries (CR7) 2018; 24 Krekorian, Fruhwirth, Srinivas, Figdor, Heskamp, Witney, Aarntzen (CR5) 2019; 9 Wissler, Ehlerding, Lyu, Zhao, Zhang, Eshraghi, Buuh, McGuth, Guan, Engle, Bartlett, Voelz, Cai, Wang (CR17) 2019; 16 De Silva, Kumar, Lisok (CR15) 2018; 15 Donnelly, Smith, Morin, Lipovšek, Gokemeijer, Cohen, Lafont, Tran, Cole, Wright, Kim, Pena, Kukral, Dischino, Chow, Gan, Adelakun, Wang, Cao, Leung, Bonacorsi, Hayes (CR18) 2018; 59 Davis, Patel (CR6) 2019; 7 CR9 Schumacher, Kesmir, van Buuren (CR1) 2015; 27 Hu, Kuan, Hanyu, Masayuki, Xie, Zhang, Nagatsu, Kotaro, Suzuki, Hisashi, Zhang (CR16) 2019; 55 Knowles, Wu (CR10) 2012; 30 Xu, Poggio, Jin, Shi, Forester, Wang, Stumpf, Xue, Devericks, So, Nguyen, Griselin, Gordan, Umetsu, Reich, Worland, Asthana, Barna, Webster, Cunningham, Ruggero (CR13) 2019; 25 Patel, Kurzrock (CR2) 2015; 14 Havel, Chowell, Chan (CR3) 2019; 19 Niemeijer, Leung, Huisman, Bahce, Hoekstra, van Dongen, Boellaard, du, Hayes, Smith, Windhorst, Hendrikse, Poot, Vugts, Thunnissen, Morin, Lipovsek, Donnelly, Bonacorsi, Velasquez, de Gruijl, Smit, de Langen (CR8) 2018; 9 Moroz, Lee, Wang, Hsiao, Sevillano, Truillet, Craik, Fong, Wang, Evans (CR12) 2018; 29 Hu, Shively, Raubitschek (CR14) 1996; 56 Ehlerding, England, McNeel, Cai (CR4) 2016; 57 Truillet, Oh, Yeo, Lee, Huynh, Wei, Parker, Blakely, Sevillano, Wang, Shen, Olivas, Jami, Moroz, Jego, Jaumain, Fong, Craik, Chang, Bivona, Wang, Evans (CR11) 2018; 29 HL Wissler (1527_CR17) 2019; 16 F Bensch (1527_CR7) 2018; 24 DJ Donnelly (1527_CR18) 2018; 59 A Moroz (1527_CR12) 2018; 29 JJ Havel (1527_CR3) 2019; 19 RA De Silva (1527_CR15) 2018; 15 K Hu (1527_CR16) 2019; 55 EB Ehlerding (1527_CR4) 2016; 57 C Truillet (1527_CR11) 2018; 29 SP Patel (1527_CR2) 2015; 14 AA Davis (1527_CR6) 2019; 7 AT Mayer (1527_CR19) 2017; 58 TN Schumacher (1527_CR1) 2015; 27 Y Xu (1527_CR13) 2019; 25 AN Niemeijer (1527_CR8) 2018; 9 SM Knowles (1527_CR10) 2012; 30 M Krekorian (1527_CR5) 2019; 9 S Hu (1527_CR14) 1996; 56 1527_CR9 |
| References_xml | – volume: 16 start-page: 2028 year: 2019 end-page: 2036 ident: CR17 article-title: Site-specific immuno-PET tracer to image PD-L1 publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.9b00010 – volume: 25 start-page: 301 year: 2019 end-page: 311 ident: CR13 article-title: Translation control of the immune checkpoint in cancer and its therapeutic targeting publication-title: Nat Med doi: 10.1038/s41591-018-0321-2 – volume: 29 start-page: 3476 year: 2018 end-page: 3482 ident: CR12 article-title: A preclinical assessment of (89)Zr-atezolizumab identifies a requirement for carrier added formulations not observed with (89)Zr-C4 publication-title: Bioconjug Chem doi: 10.1021/acs.bioconjchem.8b00632 – volume: 30 start-page: 3884 year: 2012 end-page: 3892 ident: CR10 article-title: Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology publication-title: J Clin Oncol doi: 10.1200/JCO.2012.42.4887 – volume: 14 start-page: 847 year: 2015 end-page: 856 ident: CR2 article-title: PD-L1 expression as a predictive biomarker in cancer immunotherapy publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-14-0983 – volume: 9 start-page: 7924 year: 2019 end-page: 7947 ident: CR5 article-title: Imaging of T-cells and their responses during anti-cancer immunotherapy publication-title: Theranostics doi: 10.7150/thno.37924 – volume: 58 start-page: 538 year: 2017 end-page: 546 ident: CR19 article-title: Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging publication-title: J Nucl Med doi: 10.2967/jnumed.116.177659 – volume: 19 start-page: 133 year: 2019 end-page: 150 ident: CR3 article-title: The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy publication-title: Nat Rev Cancer doi: 10.1038/s41568-019-0116-x – volume: 9 start-page: 4664 year: 2018 ident: CR8 article-title: Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer publication-title: Nat Commun doi: 10.1038/s41467-018-07131-y – volume: 57 start-page: 1487 year: 2016 end-page: 1492 ident: CR4 article-title: Molecular imaging of immunotherapy targets in cancer publication-title: J Nucl Med doi: 10.2967/jnumed.116.177493 – volume: 55 start-page: 4162 year: 2019 end-page: 4165 ident: CR16 article-title: Developing native peptide-based radiotracers for PD-L1 PET imaging and improving imaging contrast by pegylation publication-title: Chem Commun (Camb) doi: 10.1039/C9CC00445A – ident: CR9 – volume: 24 start-page: 1852 year: 2018 end-page: 1858 ident: CR7 article-title: (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer publication-title: Nat Med doi: 10.1038/s41591-018-0255-8 – volume: 59 start-page: 529 year: 2018 end-page: 535 ident: CR18 article-title: Synthesis and biologic evaluation of a novel (18)F-labeled adnectin as a PET radioligand for imaging PD-L1 expression publication-title: J Nucl Med doi: 10.2967/jnumed.117.199596 – volume: 15 start-page: 3946 year: 2018 end-page: 3952 ident: CR15 article-title: Peptide-based (68)Ga-PET radiotracer for imaging PD-L1 expression in cancer publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.8b00399 – volume: 29 start-page: 96 year: 2018 end-page: 103 ident: CR11 article-title: Imaging PD-L1 expression with ImmunoPET publication-title: Bioconjug Chem doi: 10.1021/acs.bioconjchem.7b00631 – volume: 56 start-page: 3055 year: 1996 end-page: 3061 ident: CR14 article-title: Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts publication-title: Cancer Res – volume: 27 start-page: 12 year: 2015 end-page: 14 ident: CR1 article-title: Biomarkers in cancer immunotherapy publication-title: Cancer Cell doi: 10.1016/j.ccell.2014.12.004 – volume: 7 start-page: 278 year: 2019 ident: CR6 article-title: The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0768-9 – ident: 1527_CR9 doi: 10.2967/jnumed.119.240895 – volume: 27 start-page: 12 year: 2015 ident: 1527_CR1 publication-title: Cancer Cell doi: 10.1016/j.ccell.2014.12.004 – volume: 29 start-page: 96 year: 2018 ident: 1527_CR11 publication-title: Bioconjug Chem doi: 10.1021/acs.bioconjchem.7b00631 – volume: 59 start-page: 529 year: 2018 ident: 1527_CR18 publication-title: J Nucl Med doi: 10.2967/jnumed.117.199596 – volume: 58 start-page: 538 year: 2017 ident: 1527_CR19 publication-title: J Nucl Med doi: 10.2967/jnumed.116.177659 – volume: 30 start-page: 3884 year: 2012 ident: 1527_CR10 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.42.4887 – volume: 9 start-page: 7924 year: 2019 ident: 1527_CR5 publication-title: Theranostics doi: 10.7150/thno.37924 – volume: 24 start-page: 1852 year: 2018 ident: 1527_CR7 publication-title: Nat Med doi: 10.1038/s41591-018-0255-8 – volume: 56 start-page: 3055 year: 1996 ident: 1527_CR14 publication-title: Cancer Res – volume: 7 start-page: 278 year: 2019 ident: 1527_CR6 publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0768-9 – volume: 55 start-page: 4162 year: 2019 ident: 1527_CR16 publication-title: Chem Commun (Camb) doi: 10.1039/C9CC00445A – volume: 29 start-page: 3476 year: 2018 ident: 1527_CR12 publication-title: Bioconjug Chem doi: 10.1021/acs.bioconjchem.8b00632 – volume: 9 start-page: 4664 year: 2018 ident: 1527_CR8 publication-title: Nat Commun doi: 10.1038/s41467-018-07131-y – volume: 25 start-page: 301 year: 2019 ident: 1527_CR13 publication-title: Nat Med doi: 10.1038/s41591-018-0321-2 – volume: 16 start-page: 2028 year: 2019 ident: 1527_CR17 publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.9b00010 – volume: 19 start-page: 133 year: 2019 ident: 1527_CR3 publication-title: Nat Rev Cancer doi: 10.1038/s41568-019-0116-x – volume: 14 start-page: 847 year: 2015 ident: 1527_CR2 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-14-0983 – volume: 57 start-page: 1487 year: 2016 ident: 1527_CR4 publication-title: J Nucl Med doi: 10.2967/jnumed.116.177493 – volume: 15 start-page: 3946 year: 2018 ident: 1527_CR15 publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.8b00399 |
| SSID | ssj0017123 |
| Score | 2.3416204 |
| Snippet | Purpose
The swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative... PurposeThe swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies... The swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to... |
| SourceID | unpaywall pubmedcentral proquest crossref springer |
| SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 1553 |
| SubjectTerms | Antibodies Cancer Cancer immunotherapy Comparative studies Deferoxamine Genetic engineering Hepatocellular carcinoma Image quality Imaging Immune checkpoint inhibitors Immunoglobulin G Immunotherapy Liver cancer Low molecular weights Medicine Medicine & Public Health Molecular weight Organs PD-L1 protein Radioactive tracers Radioisotopes Radiology Research Article Tumors Zirconium isotopes |
| SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-NTuLjgc8hCgMZiTeWronz1ccKVg20TlVZxXiKHNuBisypaKIx_nrunI_SPUzs2Y4c5-58v_jufgfwzkWvE3sqcNQw0g6ektKJM5tFmI2CbJTJIKPi5OlpeLzwP58H5zvgtrUwNmlfpsuByS8GZvnD5lauLuRhmyd2GIXE5-Lfgd0wQPjdg93F6Wz8reZFDR3EFzbCGYdD0gCvKZSpy-VcokSkH6YhdXN1-LYz2iDM6_mRXZD0AdyrzEpcXYo8_8cPTR7BvN1BnX7yc1CV6UD-uUbueKstPoaHDSpl43roCexo8xTuTpu4-zP4PTaspS9hRcY-oUzzwj5iymVaqCs2seB3zb5U3ylktWaCzYtcMwTFbGovInFrbPbROXEZXf6yk-KSTdvmvOyrvaJls6MzNhdqWeAXkYhM92AxOTr7cOw0PRsc6Qdu6bhqKCLfFynnoZYITxR1nkhdTrlZ2ssknii-QuCAB63iOtJxJAKuR9QoUGvp8ufQM4XRL4CpOEyFDvxUeppIbETqhyoTnkbQQaw_fXBb4SWyITSnvhp5sqFiJoEnKPDECjzhfXjfPbOq6TxunL3f6kTSmPY68fyIR3EwinH4bTeMRkmRFmF0UdEchHEc3Ujch2hLl7pVidZ7ewRVwdJ7N9Lvw0GrdZvFb3rXg04z_2NrL283_RXc98hubB7PPvTKX5V-jWisTN809vcX0M4tPw priority: 102 providerName: Unpaywall |
| Title | An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers |
| URI | https://link.springer.com/article/10.1007/s11307-020-01527-3 https://www.proquest.com/docview/2473785983 https://www.proquest.com/docview/2435531118 https://pubmed.ncbi.nlm.nih.gov/PMC7669684 https://www.ncbi.nlm.nih.gov/pmc/articles/7669684 |
| UnpaywallVersion | submittedVersion |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1860-2002 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017123 issn: 1860-2002 databaseCode: AFBBN dateStart: 20050101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1860-2002 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017123 issn: 1860-2002 databaseCode: AGYKE dateStart: 20050101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1860-2002 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017123 issn: 1860-2002 databaseCode: U2A dateStart: 20050101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgk_h4QHxqhTEZiTdmqY7tOH3MoGXAWlVjFdtT5NgOqxQlE2217b_fnZekFKEJnqLIH3FyPvsX393vCHnPYddJIqeY62vPYJW0LCmCF2ExUMWgsKrA4OTxJD6cya-n6rQJClu03u6tSTKs1OtgN46Ehvi708dcrEzcJ9sK6bxgFs-itLMdaB6SuoEqxwzQRtSEyvy9j83taI0x__SQ7Mykj8nDVXVhri9NWf62E42ekicNhKTprcyfkXu-ek4ejBsj-QtylVa05RqhdUG_gADKOjSplvO8dtd0FJDqgn5f_UT70oIaelyXngKCpeNwagijoNNP7IhTPKmlR_UlHbeZdOmPcJ5Kp8MTemzcvIbBW4CRL8lsNDz5eMiaBAvMSsWXjLu-0VKaXIjYW8ASDtNE5FygI5WPCgvqLx3s8rAqOuG1T7RRwg8wq5_3lotXZKuqK79DqEvi3Hglcxt5ZJwxuYxdYSIPCAEpenqEt985sw37OCbBKLM1bzLKJgPZZEE2meiRD12bi1vujTtr77biyxo9XGSR1EInapBA8buuGDQIzSKm8vUK6wDmErDmJz2iN8TePRU5uDdLqvl54OLWMbILyR7ZbyfI-uF3jXW_m0T_8Gqv_6_3N-RRhFM8ON3skq3lr5V_C9Bpme-R7XR0cDDB6-ezb8O9oDlwN5tM07MbI3ARqw |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED9BJ7HtYXwNUTbASLyxTE3sxOljBS0da6ZptGI8RY7tsIoomdZEY_z1nN0kpROa2LO_z2f7Z9_5dwDvXTx1Qk_5jupx7eAuKZ0wtV6Ead9P-6n0U_M5OToJxjP25dw_rz-FLRpv98YkaXfq1Wc31xAamutOz8RidehD2GB4QfE6sDH4_P142FoPuGvDuuFiDhzEG179WebftawfSCuUedtHsjWUbsNmlV-Km2uRZX-dRaPHMGtGsXRB-XlYlcmh_H2L4PG-w3wCOzU4JYOlNj2FBzp_Bo-i2vz-HH4NctKwmJAiJUc4tVlhi-TlPCnUDRlZDLwgX6sfxnK1IIKcFZkmiI1JZN8jsTPk9JMzcYl5AyaT4ppETYxe8s2-1JLT4ZScCTUvUCgSAeouzEbD6cexU4ducCTz3dJxVU9wxkRCaaAlohRlAlAkLjUuWtpLJW4sTCF-wP1WUc11yIVPdd_EC9RauvQFdPIi1y-BqDBIhPZZIj1tuGxEwgKVCk8j9jDkP11wm_mLZc1rbsJrZPGKkdmINEaRxlakMe3Ch7bM5ZLV487c-41axPUKX8Qe45SHfj_E5HdtMq5NY3ARuS4qkwfRHMXTJOwCX1OntlXD7r2eks8vLMs3DwxvEevCQaMnq8bv6utBq5z_MbRX96v9LWyOp9EknhydHO_Blme01Lr27EOnvKr0awRoZfKmXo9_ACxULL8 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELZgSGM8IH6KwgAj8cas1bETp48VW7VBO1VjFXuLHNuBSpFTranG_nvu3CRdEZrg2Y7t5O7sL7677wj5yOHUSSMbM9tXjsEuaVhahCjCYhAXg8LEBSYnT86Sk5n8chlf3sriD9HurUtyndOALE2-PlzY4nCT-MaR3BB_ffpYl5WJ--SBRKIE0OhZNOz8CIqHAm9g1gkD5BE1aTN_H2P7aNrgzT-jJTuX6SPycOUX-uZal-WtU2n0hDxu4CQdruX_lNxz_hnZnTQO8-fk19DTlneEVgU9BWGUVXjE1_O8sjd0FFDrkn5b_UBf05Jqel6VjgKapZNwgwiroNMjNuYUb23puLqmk7aqLv0e7lbp9PiCnms7r2DxBiDlCzIbHV98PmFNsQVmZMxrxm1fKyl1LkTiDOAKiyUjci4wqMpFhYGtQFo48WGHtMIplyodCzfACn_OGS5ekh1fefeKUJsmuXaxzE3kkH1G5zKxhY4coAWk6-kR3n7nzDRM5FgQo8w2HMoomwxkkwXZZKJHPnXPLNY8HHf23m_FlzU2ucwiqYRK40EKzR-6ZrAmdJFo76oV9gH8JWD_T3tEbYm9mxX5uLdb_Pxn4OVWCTINyR45aBVkM_ldaz3olOgfXu31_43-nuxOj0bZ-PTs6xuyF6G2h1icfbJTX63cW0BUdf4uGM1vBEUUEw |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-NTuLjgc8hCgMZiTeWronz1ccKVg20TlVZxXiKHNuBisypaKIx_nrunI_SPUzs2Y4c5-58v_jufgfwzkWvE3sqcNQw0g6ektKJM5tFmI2CbJTJIKPi5OlpeLzwP58H5zvgtrUwNmlfpsuByS8GZvnD5lauLuRhmyd2GIXE5-Lfgd0wQPjdg93F6Wz8reZFDR3EFzbCGYdD0gCvKZSpy-VcokSkH6YhdXN1-LYz2iDM6_mRXZD0AdyrzEpcXYo8_8cPTR7BvN1BnX7yc1CV6UD-uUbueKstPoaHDSpl43roCexo8xTuTpu4-zP4PTaspS9hRcY-oUzzwj5iymVaqCs2seB3zb5U3ylktWaCzYtcMwTFbGovInFrbPbROXEZXf6yk-KSTdvmvOyrvaJls6MzNhdqWeAXkYhM92AxOTr7cOw0PRsc6Qdu6bhqKCLfFynnoZYITxR1nkhdTrlZ2ssknii-QuCAB63iOtJxJAKuR9QoUGvp8ufQM4XRL4CpOEyFDvxUeppIbETqhyoTnkbQQaw_fXBb4SWyITSnvhp5sqFiJoEnKPDECjzhfXjfPbOq6TxunL3f6kTSmPY68fyIR3EwinH4bTeMRkmRFmF0UdEchHEc3Ujch2hLl7pVidZ7ewRVwdJ7N9Lvw0GrdZvFb3rXg04z_2NrL283_RXc98hubB7PPvTKX5V-jWisTN809vcX0M4tPw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+Analysis+of+Isoclonal+Antibody+Formats+Suggests+a+Role+for+Measuring+PD-L1+with+Low+Molecular+Weight+PET+Radiotracers&rft.jtitle=Molecular+imaging+and+biology&rft.au=Wei%2C+Junnian&rft.au=Wang%2C+Yung-Hua&rft.au=Lee%2C+Chia+Yin&rft.au=Truillet%2C+Charles&rft.date=2020-12-01&rft.issn=1860-2002&rft.eissn=1860-2002&rft.volume=22&rft.issue=6&rft.spage=1553&rft_id=info:doi/10.1007%2Fs11307-020-01527-3&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1536-1632&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1536-1632&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1536-1632&client=summon |